HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

External beam radiotherapy synergizes ¹⁸⁸Re-liposome against human esophageal cancer xenograft and modulates ¹⁸⁸Re-liposome pharmacokinetics.

Abstract
External beam radiotherapy (EBRT) treats gross tumors and local microscopic diseases. Radionuclide therapy by radioisotopes can eradicate tumors systemically. Rhenium 188 ((188)Re)-liposome, a nanoparticle undergoing clinical trials, emits gamma rays for imaging validation and beta rays for therapy, with biodistribution profiles preferential to tumors. We designed a combinatory treatment and examined its effects on human esophageal cancer xenografts, a malignancy with potential treatment resistance and poor prognosis. Human esophageal cancer cell lines BE-3 (adenocarcinoma) and CE81T/VGH (squamous cell carcinoma) were implanted and compared. The radiochemical purity of (188)Re-liposome exceeded 95%. Molecular imaging by NanoSPECT/CT showed that BE-3, but not CE81T/VGH, xenografts could uptake the (188)Re-liposome. The combination of EBRT and (188)Re-liposome inhibited tumor regrowth greater than each treatment alone, as the tumor growth inhibition rate was 30% with EBRT, 25% with (188)Re-liposome, and 53% with the combination treatment at 21 days postinjection. Combinatory treatment had no additive adverse effects and significant biological toxicities on white blood cell counts, body weight, or liver and renal functions. EBRT significantly enhanced the excretion of (188)Re-liposome into feces and urine. In conclusion, the combination of EBRT with (188)Re-liposome might be a potential treatment modality for esophageal cancer.
AuthorsChih-Hsien Chang, Shin-Yi Liu, Chih-Wen Chi, Hsiang-Lin Yu, Tsui-Jung Chang, Tung-Hu Tsai, Te-Wei Lee, Yu-Jen Chen
JournalInternational journal of nanomedicine (Int J Nanomedicine) Vol. 10 Pg. 3641-9 ( 2015) ISSN: 1178-2013 [Electronic] New Zealand
PMID26056445 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Liposomes
  • Radioisotopes
  • Radiopharmaceuticals
  • Rhenium
Topics
  • Adenocarcinoma (drug therapy, pathology, radiotherapy)
  • Animals
  • Antineoplastic Agents (chemistry, pharmacokinetics, pharmacology)
  • Carcinoma, Squamous Cell (drug therapy, pathology, radiotherapy)
  • Combined Modality Therapy
  • Esophageal Neoplasms (drug therapy, pathology, radiotherapy)
  • Humans
  • Liposomes (chemistry, pharmacokinetics)
  • Male
  • Mice, Inbred BALB C
  • Nanoparticles (administration & dosage, chemistry)
  • Radioisotopes (pharmacokinetics, therapeutic use)
  • Radiopharmaceuticals (pharmacokinetics, therapeutic use)
  • Radiotherapy (methods)
  • Rhenium (chemistry, pharmacokinetics, pharmacology)
  • Tissue Distribution
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: